Dr. Reddy’s Laboratories announced the launch of Naproxen and Esomeprazole Magnesium Delayed-Release Tablets, the generic equivalent to Vimovo® (Horizon Pharma).
The product combines naproxen, a nonsteroidal anti-inflammatory drug (NSAID), and esomeprazole, a proton pump inhibitor. The treatment is indicated for adult patients requiring naproxen for symptomatic relief of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and esomeprazole magnesium to decrease the risk of developing naproxen-associated gastric ulcers.
The prescribing information for Naproxen and Esomeprazole Magnesium Delayed-Release Tablets contains a Boxed Warning regarding an increased risk of serious cardiovascular and gastrointestinal events; use is contraindicated in the setting of coronary artery bypass graft (CABG) surgery.
The tablets are available in 375mg/20mg and 500mg/20mg strengths in 60-count bottles.
“We are excited to be a part of forming the first generic market for Vimovo Tablets and to provide an affordable treatment alternative for patients,” said Marc Kikuchi, CEO for Dr Reddy’s North American Generics.
For more information visit drreddys.com.
This article originally appeared on MPR